Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-12-10

Clinical Trial Update: Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD

View source ↗

Summary

Post-marketing surveillance study of tolvaptan in autosomal dominant polycystic kidney disease has completed and posted its results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • JYNARQUE (tolvaptan)

Snippet

Sponsor: Otsuka Pharmaceutical Co., Ltd. | Conditions: Polycystic Kidney, Autosomal Dominant | Status: COMPLETED | Results posted: 2025-12-10